Real-world SARS CoV-2 testing in Northern England during the first wave of the COVID-19 pandemic.
COVID-19
Novel coronavirus
Public health
SARS CoV-2
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
13
01
2021
revised:
12
04
2021
accepted:
14
04
2021
pubmed:
24
4
2021
medline:
25
6
2021
entrez:
23
4
2021
Statut:
ppublish
Résumé
SARS-CoV-2 emerged in South Asia in 2019 and has resulted in a global pandemic. Public Health England (PHE) Manchester rapidly escalated testing for SARS-CoV-2 in the highest COVID-19 incidence location in England. The results of the PHE Manchester SARS-CoV-2 surveillance during the first wave are presented. Retrospective data were collected for patients fitting the PHE SARS-CoV-2 case definition from 11th February to 31st August 2020. Respiratory tract, tissue, faecal, fluid and cerebrospinal (CSF) samples were tested for SARS-CoV-2 by a semi-quantitative real-time reverse-transcription PCR. Of the 204,083 tests for SARS-CoV-2, 18,011 were positive demonstrating a positivity of 8.90%. Highest positivity was in nasal swabs (20.99%) followed by broncheo-alveolar lavage samples (12.50%). None of the faecal, fluid or CSF samples received were positive for SARS-CoV-2. There was a high incidence of SARS-CoV-2 patients in the North-West of England during the first UK wave of the Covid-19 pandemic. Highest positivity rate was in nasal specimens suggesting this is the optimum sample type within this dataset for detecting SARS-CoV-2. Further studies are warranted to assess the utility of testing faecal, fluid and CSF samples. Rapid escalation of testing via multiple platforms was required to ensure prompt diagnosis and isolate infected cases to reduce transmission of the virus.
Identifiants
pubmed: 33892016
pii: S0163-4453(21)00199-7
doi: 10.1016/j.jinf.2021.04.013
pmc: PMC8058098
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-91Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors declare they have no conflicts of interests or anything to declare.
Références
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Innovation (N Y). 2020 Nov 25;1(3):100061
pubmed: 33169119
Chest. 2020 Nov;158(5):1804-1805
pubmed: 33160519
EBioMedicine. 2020 Sep;59:102903
pubmed: 32718896
Clin Infect Dis. 2021 Jun 1;72(11):e921
pubmed: 32986798
Front Med (Lausanne). 2020 Jun 18;7:334
pubmed: 32626720
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Lancet. 2020 Mar 14;395(10227):e46
pubmed: 32113507
Nat Microbiol. 2020 Oct;5(10):1299-1305
pubmed: 32651556
Am J Trop Med Hyg. 2020 Nov;103(5):2019-2021
pubmed: 32996443
Ann Intern Med. 2020 Jun 16;172(12):832-834
pubmed: 32227141
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Euro Surveill. 2021 Feb;26(6):
pubmed: 33573710
J Infect. 2021 Jun;82(6):276-316
pubmed: 33662408
PLoS One. 2021 Feb 4;16(2):e0246637
pubmed: 33539485